Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01

By sjmartinez • September 13, 2024

Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Zhang Q, Tsurutani J, Kalinsky K, Rubini Liedke PE, Xu L, Fairhurst RM, Khan S, Denduluri N, Rugo HS, Xu B, Pistilli B; TROPION-Breast01 Investigators. Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. J Clin Oncol. 2024 Sep 12:JCO2400920. doi: 10.1200/JCO.24.00920. Epub ahead of print. PMID: 39265124.

Tags: Hematology/Oncology, Publications

Developing remote patient monitoring infrastructure using commercially available cloud platforms

Cao M, Ramezani R, Katakwar VK, Zhang W, Boda D, Wani M, Naeim A. Developing remote patient monitoring infrastructure using commercially available cloud platforms. Front[...]

INteractive survivorship program to improve health care REsources [INSPIRE]: A study protocol testing a digital intervention with stepped care telehealth to improve outcomes for adolescent and young adult survivors

Yi JC, Ballard S, Walsh C, Friedman DN, Ganz PA, Jacobs LA, Partridge AH, Mitchell SA, Leisenring WM, Syrjala KL, Baker KS. INteractive survivorship program[...]

Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma

Bitar R, Salem R, Finn R, Greten TF, Goldberg SN, Chapiro J. Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma. Radiology. 2024 Nov;313(2):e232875. doi:[...]